Drugs / GSK2556286
GSK2556286
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04472897 | Oct 2020 → Nov 2024 | tuberculosis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2556286 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04472897 ↗ |
| Known as | GSK2556286A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650308 ↗ |
| Known as | GSK286 | “This first-in-human study (ClinicalTrials.gov identifier: NCT04472897) evaluated the safety, tolerability, pharmacokinetics, and food effect of single ascending and repeat oral...” PMID 42139005 ↗ May 2026 |
| Modality | Small molecule | — CHEMBL4650308 ↗ |
| Route | Oral | “single ascending and repeat oral doses of GSK2556286” PMID 42139005 ↗ May 2026 |